endoscopic drainage
ProcedureChoice of modalities: ERCP, EUS-guided gallbladder drainage (EUS-GBD), EUS-guided choledochoduodenostomy (EUS-CDS), and EUS-guided hepaticogastrostomy (EUS-HGS)
NCT Number: NCT07817602
The incidence of pancreatic cancer is rising. Tumor-induced obstruction of the distal bile duct is a common complication, occurring during the course of nearly 80% of pancreatic tumors. Approximately 10% of these obstructions are complicated by cholangitis, and jaundice is associated with tumor progression due to the resulting impairment of cellular immunity. The standard treatment for distal bile duct obstruction is transpapillary drainage via endoscopic retrograde cholangiopancreatography (ERCP). This procedure is performed under general anesthesia and carries a failure rate of 15% and a complication rate of up to 9%. In recent years, alternative techniques for endoscopic ultrasound (EUS)-guided biliary drainage have been developed, such as hepaticogastrostomy, choledochoduodenostomy, and cholecystogastrostomy. These EUS-guided biliary drainage techniques overcome failures caused by malignant duodenal stenosis (present in up to 25% of such cases), with lower morbidity and greater clinical efficacy compared to percutaneous radiological drainage. EUS-guided biliary drainage techniques have been simplified by the advent of lumen-apposing metal stents (LAMS), which have enabled technical success rates of nearly 90%. The two techniques most frequently described in the literature are choledochoduodenostomy (CDS)-connecting the common bile duct to the duodenal bulb-and hepaticogastrostomy (HGS)-connecting the left intrahepatic bile ducts to the stomach. CDS is less morbid and technically easier to perform but has limitations in cases of duodenal stenosis, an insufficiently dilated common bile duct, or an unfavorable puncture window. For a long time, endoscopic gallbladder drainage via cholecystogastrostomy (CGS) was restricted to treating acute cholecystitis in patients ineligible for surgery; its use for biliary drainage in cases of malignant jaundice remained anecdotal, for reasons that were not clearly identified. The investigators were the first to publish a multicenter comparative study contrasting CGS with CDS following failed ERCP for distal malignant biliary obstruction. This study demonstrated comparable technical and clinical success rates for both techniques, with a better long-term morbidity profile favoring CGS. More recently, a large-scale international multicenter study validated the efficacy of gallbladder drainage compared to common bile duct drainage as a first-line approach. The study team previously launched the COPPINE cohort (Prospective Cohort of Innovative Endoscopic Procedures) in 2024, aiming to continuously enroll all patients undergoing innovative endoscopic procedures, including endoscopic ultrasound-guided biliary drainage. This study aims to prospectively compare the clinical outcomes of patients with malignant distal biliary obstruction based on the biliary drainage technique they received.
Trial opening soon.
Get Notified18 year and older
All sexes
Observational
CHU Dupuytren, Limoges, France
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Choice of modalities: ERCP, EUS-guided gallbladder drainage (EUS-GBD), EUS-guided choledochoduodenostomy (EUS-CDS), and EUS-guided hepaticogastrostomy (EUS-HGS)
Time frame: Month 12
Yes/no, according to Guidelines on Reporting Outcomes in Biliary Drainage Trials
Time frame: Month 12
Yes/no, where stent malposition or incomplete deployment requiring conversion or rescue maneuvers will not be considered technical successes.
Time frame: Month 12
Yes/no, measured as reduction of ≥50% in total bilirubin level compared to the pre-procedural value within 2 weeks of the index procedure, or achieving a total bilirubin level of less than 25% of the pre-procedural value within 6 weeks
Time frame: Month 12
Yes/no for use of: double-guidewire technique, precut, infundibulotomy, other
Time frame: Month 12
Segment (II or III) with best bilirubin levels (µmol/L)
Time frame: Month 12
TNM staging
Time frame: Month 12
cm
Time frame: Month 12
Yes/no
Time frame: Month 12
mm
Time frame: Month 12
Classed as: resident, senior registrar/assistant, junior attending (<500 procedures), or experienced attending (>500 procedures)
Time frame: Month 12
Classed as: pylorus, D1, D2, D3, D4, jejunum, or multiple segments
Time frame: Month 12
cm
Time frame: Month 12
yes/no
Time frame: Month 12
Yes/no, where success is classed as ≥50% reduction in total bilirubin levels compared to the pre-procedural value within 2 weeks of the index procedure, or achieving a total bilirubin level below 25% of the pre-procedural value within 6 weeks.
Time frame: Day 0, Day 14, Day 45, Month 6, and Month 12.
µmol/l
Time frame: Month 12
Yes/no
Time frame: Month 12
Days
Time frame: Month 12
Classed as: ERCP, HGS, CGS, CDS, radiological drainage
Time frame: Month 12
Measured from day of the endoscopic procedure and Day 1 of chemotherapy
Time frame: Month 12
Yes/no
Time frame: Month 12
Yes/no
Time frame: Month 12
Yes/no
Time frame: Month 12
Yes/no
Time frame: Month 12
Yes/no
Time frame: Month 12
Yes/no
Time frame: Month 12
Classed as: ERCP, HGS, CDS, CGS, radiological drainage
Time frame: Month 12
Classed as cholecystogastric or cholecystoduodenal
Time frame: Month 12
Number
Time frame: Month 12
Classed as: early: <30 days; late: ≥30 days
Time frame: Month 12
Classed as: procedure-related, disease-related, or unrelated
Time frame: Month 12
According to the AGREE classification (grades I to V) and the ASGE lexicon (Nass et al. 2022); - Specifically reported adverse events will include: cholangitis, bile leak, hemorrhage, pneumoperitoneum, perforation, stent migration, stent occlusion, cholecystitis (EUS-GBD arm), and buried stent syndrome. Chemotherapy interruption directly attributable to a drainage-related event will be documented as an indirect adverse event.
Time frame: Month 12
Time frame: Month 12
Time frame: Month 12
Including the initial procedure, expressed in euros; calculated from the perspective of the healthcare system (hospitals + health insurance) and including the costs of hospitalizations, transport, and endoscopic procedures (initial procedure and any re-interventions).
Time frame: Month 12
Defined as the actual performance of a laparotomy or laparoscopy with the aim of pancreatic resection
Time frame: Month 12
Defined as the performance of a pancreatic resection procedure
Time frame: Month 12
yes/no (including venous or arterial resection and/or reconstruction)
Time frame: Month 12
Yes/no
Time frame: Month 12
Resection margin status: R0 / R1
Time frame: Month 12
Number of lymph nodes analyzed: continuous quantitative variable (absolute number)
Time frame: Month 12
measured according to the classification in effect at the time of surgery
Time frame: Month 12
Occurrence of at least one severe postoperative complication, defined as: Clavien-Dindo ≥ III
Time frame: Day 30
Yes/no
Time frame: Day 90
Yes/no
Time frame: Month 24
Percentage of centers that enrolled at least 5 patients within the scheduled timeframe
Time frame: Month 12
Calculated as: number of patients enrolled / number of eligible patients identified
Time frame: Month 24
Percentage
Contact information is provided by the study sponsor or research team.
Centre Hospitalier Universitaire de Nīmes
Other
Acronym: PROBILEUS
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07811791
Biliary Drainage, Biliary Tract Diseases
Hsinchu, Taiwan
View Trial DetailsNCT07329803
Bile Duct Diseases, Biliary Drainage
View Trial DetailsNCT07667166
Acute Cholangitis, Biliary Drainage
Hyderabad, Telangana, India
View Trial DetailsNCT05122858
Biliary Drainage, Echography Ultrasound
Paris, France
View Trial Details